Abstract 433P
Background
Previous researches have reported on the protective effect of aspirin on different types of cancers. However, evidence from observational studies can be biased by multiple confounding factors. Also, it remains unclear whether aspirin use is casually related to a decreased cancer risk. Consequently, we conducted Mendelian randomization analyses, using single nucleotide polymorphisms (SNPs) as instrumental variables to investigate the casual effect of aspirin on different types of cancers.
Methods
Mendelian randomization analyses were conducted using pooled statistics from corresponding researches and several large-scale consortia. Inverse-variance weighted, MR-Egger and weighted median methods were utilized to evaluate the possible causal relationship between aspirin and the observed reduction in cancer risk. Results were shown by odds ratios (OR) and their corresponding 95% CIs. Analyses were conducted using the package “TwoSampleMR” in R.
Results
A total of 19 cancers corresponding to 344,392 cases and 5,424,758 controls were included in the final analysis. In contrast to the lower risk for various cancer types reported in conventional observational studies, our MR results only showed a decreased risk in lung cancer [odds ratio (OR) 0.0418; 95% confidence interval (CI) 0.0031-0.5638; P=0.0168] and squamous cell lung cancer [OR=0.002; 95% CI 1.2145×10-5-0.3009; P=0.0153]. Insignificant results were observed in other types of cancers including lung adenocarcinoma, breast cancer, ovarian cancer, colon cancer, kidney cancer, liver cancer, esophageal cancer, oral cancer, pancreas cancer, rectal cancer, malignant melanoma, non-melanoma skin cancer, Hodgkin’s lymphoma as well as non-Hodgkin’s lymphoma.
Conclusions
The potential effect of aspirin in cancer prevention still needs to be interpreted with cautions and aspirin is still too early to be recommended as a universal chemoprotective agent for primary cancer prevention. Further randomized controlled trials with a more rigorous design are warranted in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session